Reported 28 days ago
Merck & Co. (MRK), a leading pharmaceutical company, faces challenges from rising tariffs amid a volatile global market that strains supply chains and increases costs. With key drug Keytruda's patent expiring in 2028, Merck has initiated a $3 billion cost-cutting plan to maintain its dividend legacy. Despite a recent decline in stock price and mixed financial results, the company aims to innovate and diversify its pipeline, including a significant acquisition of Verona Pharma. Analysts are cautiously optimistic about Merck's future as it navigates these hurdles.
Source: YAHOO